A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.
Tuli R, Shiao SL, Nissen N, Tighiouart M, Kim S, Osipov A, Bryant M, Ristow L, Placencio-Hickok V, Hoffman D, Rokhsar S, Scher K, Klempner SJ, Noe P, Davis MJ, Wachsman A, Lo S, Jamil L, Sandler H, Piantadosi S, Hendifar A.
Tuli R, et al.
EBioMedicine. 2019 Feb;40:375-381. doi: 10.1016/j.ebiom.2018.12.060. Epub 2019 Jan 8.
EBioMedicine. 2019.
PMID: 30635165
Free PMC article.
Clinical Trial.